基于基因亚型的弥漫性大B细胞淋巴瘤血脂异常：一项对259例中国患者的单中心研究。

Dyslipidemia in diffuse large B-cell lymphoma based on the genetic subtypes: a single-center study of 259 Chinese patients.

作者信息

Xu Yi, Shen Huafei, Shi Yuanfei, Zhao Yanchun, Zhen Xiaolong, Sun Jianai, Li Xueying, Zhou De, Yang Chunmei, Wang Jinhan, Huang Xianbo, Wei Juying, Huang Jian, Meng Haitao, Yu Wenjuan, Tong Hongyan, Jin Jie, Xie Wanzhuo

机构信息

Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

出版信息

Front Oncol. 2023 Jun 9;13:1172623. doi: 10.3389/fonc.2023.1172623. eCollection 2023.

DOI:10.3389/fonc.2023.1172623

PMID:37384286

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10299728/

Abstract

BACKGROUND

Diffuse large B-cell lymphoma (DLBCL) is a kind of highly heterogeneous non-Hodgkin lymphoma, both in clinical and genetic terms. DLBCL is admittedly categorized into six subtypes by genetics, which contain MCD, BN2, EZB, N1, ST2, and A53. Dyslipidemia is relevant to a multitude of solid tumors and has recently been reported to be associated with hematologic malignancies. We aim to present a retrospective study investigating dyslipidemia in DLBCL based on the molecular subtypes.

RESULTS

This study concluded that 259 patients with newly diagnosed DLBCL and their biopsy specimens were available for molecular typing. Results show that the incidence of dyslipidemia (87.0%, p <0.001) is higher in the EZB subtype than in others, especially hypertriglyceridemia (78.3%, p = 0.001) in the EZB subtype. Based on the pathological gene-sequencing, patients with BCL2 gene fusion mutation are significantly correlative with hyperlipidemia (76.5%, p = 0.006) and hypertriglyceridemia (88.2%, p = 0.002). Nevertheless, the occurrence of dyslipidemia has no remarkable influence on prognosis.

CONCLUSION

In summary, dyslipidemia correlates with genetic heterogeneity in DLBCL without having a significant influence on survival. This research first connects lipids and genetic subtypes in DLBCL.

摘要

背景

弥漫性大B细胞淋巴瘤（DLBCL）是一种在临床和遗传学方面都具有高度异质性的非霍奇金淋巴瘤。公认地，DLBCL在遗传学上可分为六个亚型，即MCD、BN2、EZB、N1、ST2和A53。血脂异常与多种实体瘤相关，最近有报道称其与血液系统恶性肿瘤有关。我们旨在进行一项回顾性研究，基于分子亚型调查DLBCL中的血脂异常情况。

结果

本研究纳入了259例新诊断的DLBCL患者及其活检标本进行分子分型。结果显示，EZB亚型中血脂异常的发生率（87.0%，p<0.001）高于其他亚型，尤其是EZB亚型中的高甘油三酯血症（78.3%，p = 0.001）。基于病理基因测序，BCL2基因融合突变的患者与高脂血症（76.5%，p = 0.006）和高甘油三酯血症（88.2%，p = 0.002）显著相关。然而，血脂异常的发生对预后没有显著影响。